Novartis says Bexsero shows significant potential against meningococcal serogroup B infections

Swiss drug major Novartis (NVN: VX) says that new data from a pivotal study in more than 1,800 infants show that its candidate vaccine Bexsero (multicomponent meningococcal serogroup B vaccine) induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines.

These results also show that Bexsero can fit into various vaccination schedules in the first year of life, when the likelihood of contracting this often-deadly disease is greatest. The study also demonstrated that Bexsero has an acceptable tolerability profile.
Andrew Weiss, an analyst at Vontoble quoted by Reuters, said the vaccine could achieve peak sales of $2 billion, and estimated it has a 50% probability of success.

Positive results in toddlers and adolescents